The Medical Letter on Drugs and Therapeutics
An Inhaled Insulin (Afrezza)
March 2, 2015 (Issue: 1463)The FDA has approved an inhaled, rapid-acting, dry-powder formulation of recombinant human insulin (Afrezza – Mannkind/Sanofi) for treatment of adults with type 1 or type 2 diabetes. In patients with type 1 diabetes, the drug must be used in...more
- LD Mastrandrea. Inhaled insulin: overview of a novel route of insulin administration. Vasc Health Risk Manag 2010; 6:47.
- Drugs for type 2 diabetes. Treat Guidel Med Lett 2014; 12:17.
- J Rosenstock et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet 2010; 375:2244.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.